Pfizer Norvasc Patent Term Extension Keeps AmVaz Off The Market Until 2007
Executive Summary
Pfizer's Norvasc (amlodipine besylate) will not face competition from Dr. Reddy's calcium channel blocker AmVaz until 2007 under a federal appeals court ruling